相关实验视频

Updated: Jun 28, 2025

In Vivo Dynamics of Retinal Microglial Activation During Neurodegeneration: Confocal Ophthalmoscopic Imaging and Cell Morphometry in Mouse Glaucoma

In Vivo Dynamics of Retinal Microglial Activation During Neurodegeneration: Confocal Ophthalmoscopic Imaging and Cell Morphometry in Mouse Glaucoma

Published on: May 11, 2015

视网膜神经纤维层厚度的纵向变化在肌缩侧面硬化症和帕金森病中

Sharifah Azira Taufik¹, Norlina Ramli², Ai Huey Tan³

¹UM Eye Research Centre, Department of Ophthalmology, Universiti Malaya, Jalan Profesor Diraja Ungku Aziz, Kuala Lumpur, Malaysia.

Journal of clinical neurology (Seoul, Korea)

|April 16, 2024

概括

视网膜神经纤维层 (RNFL) 稀薄表明肌缩侧面硬化症 (ALS) 的疾病进展,但不是帕金森病 (PD). 与PD不同的是,RNFL厚度是ALS进展的潜在生物标志物.

科学领域:

神经科学是一个神经科学.
眼科医生眼科眼科
神经学神经学

背景情况:

前视觉通路越来越多地涉及到神经退行性疾病,如ALS和PD.
了解这些途径的变化可以提供有关疾病机制和进展的见解.

研究的目的:

为了研究ALS和PD患者视网膜神经纤维层 (RNFL) 厚度的纵向变化.
在这些条件下评估RNFL厚度作为疾病进展的生物标志物的潜力.

主要方法:

招募了21名ALS患者,19名PD患者和21名健康对照.
在基线和6个月后使用光学连贯性断层扫描测量RNFL厚度.
记录患者的人口统计和相关的临床分数.

主要成果:

基线RNFL在ALS患者的上方象限较薄,与对照组相比 (p=0.008).
在6个月的时间里,ALS患者的RNFL显著减轻,特别是在下方象限 (p=0.032).
在PD患者中没有观察到显著的RNFL变化,也没有发现RNFL变化和ALS功能评分之间的相关性.

结论:

RNFL厚度是跟踪ALS疾病进展的有希望的生物标志物.
由于其进展速度较慢,RNFL厚度不是PD疾病进展的重要生物标志物.

关键词:

帕金森病是帕金森病的一种疾病.骨髓缩侧面硬化症 (ALS) 是一种光学连贯性断层扫描技术视网膜神经纤维层是一种神经纤维层.

更多相关视频

Using Optical Coherence Tomography and Optokinetic Response As Structural and Functional Visual System Readouts in Mice and Rats

Using Optical Coherence Tomography and Optokinetic Response As Structural and Functional Visual System Readouts in Mice and Rats

Published on: January 10, 2019

Using Retinal Imaging to Study Dementia

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

相关概念视频

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...